News from NeuroEM

Breakthrough Technology Platform

NeuroEM's TEMT-RF technology represents a novel therapeutic approach that uses specific ultra-high frequency radio waves to target the underlying mechanisms of cognitive decline. The treatment is delivered through a lightweight cap designed for at-home use, worn for one hour twice daily. According to the company, the device uses short pulses of energy to deliver transcranial electromagnetic treatment that improves key physical factors in the brain at the root of cognitive decline.

The technology targets multiple pathways simultaneously, working to reduce cognitive decline, restore immune balance in the brain and blood, and boost energy production in brain cells—all critical elements for optimal cognitive function.

Early studies have demonstrated that TEMT-RF is safe, enhances cognitive function, and may potentially modify Alzheimer’s disease itself.

FDA Recognition and Clinical Progress

NeuroEM has achieved a significant regulatory milestone, receiving the first Breakthrough Device status from the U.S. Food and Drug Administration (FDA) specifically for treating Alzheimer’s disease. This designation is reserved for devices that provide more effective treatment for life-threatening or irreversibly debilitating diseases and represents a major validation of the technology's potential.

The company's approach is built upon a decade of groundbreaking research conducted at Tampa-based research facilities at the University of South Florida (USF).

The first commercial product has shown extraordinary promise in both preclinical and clinical studies, positioning it as a first-in-class wearable device for extending healthy longevity.

Strategic Investment and Leadership

The Series A round is led by BlueLake Partner Jamie Rutledge, who brings over 25 years of experience in technology investment and innovation. Rutledge, who also joins NeuroEM's Board of Directors, has held senior leadership roles at Dyson and Lenovo, previously leading Lenovo's Strategic Venture Capital and Open Innovation initiatives.

"NeuroEM's pioneering, non-invasive approach to treating and preventing Alzheimer's represents exactly the kind of patented, deep tech innovation we champion at BlueLake – transformative, defensible, and grounded in scientific rigor," said Rutledge. "This approach to drug-free treatment and prevention of Alzheimer's holds tremendous promise in tackling a disease that has eluded effective solutions for decades."

Chuck Papageorgiou, CEO of NeuroEM Therapeutics, emphasized the strategic value of the partnership: "Blue-Lake's support demonstrates the importance of maintaining our momentum in the execution of key clinical, regulatory, and commercial milestones on our journey toward a safe, effective, drug-free treatment for Alzheimer's dementia and other neurodegenerative diseases."

Market Positioning and Future Outlook

NeuroEM Therapeutics is a member of StartUp Health's Alzheimer's Moonshot Community and is committed to developing, clinically testing, and marketing its multi-patented TEMT-RF technologies.

The company's approach addresses a significant unmet medical need in neurodegenerative diseases, where traditional drug-based treatments have shown limited success.

The funding will fuel continued efforts across research, clinical development, engineering, and regulatory activities as the company progresses toward broader market engagement and commercialization of its innovative therapeutic platform.